{"name":"Healx","slug":"healx","ticker":"PRIVATE","exchange":"Private","domain":"healx.io","description":"Healx is a private company specializing in AI-driven drug discovery for rare diseases. They focus on developing innovative treatments for underserved patient populations. With a strong pipeline of promising candidates, Healx is poised to make a significant impact in the rare disease space. As a leader in AI-driven drug discovery, Healx is well-positioned to capitalize on the growing demand for targeted therapies.","hq":"Cambridge, UK","founded":0,"employees":"","ceo":"Tim Guilliams","sector":"AI Drug Discovery / Rare Disease","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"~$200M (last private valuation)","metrics":{"revenue":2000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Healx-101 patent cliff ($100M at risk)","drug":"Healx-101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"deal","headline":"Healx Raises $56M in Series C Funding","summary":"Healx secured $56 million in Series C funding to accelerate its AI-driven drug discovery efforts.","drugName":"","sentiment":"positive"},{"date":"2023-09-14","type":"trial","headline":"Healx Announces Positive Phase 2 Results for Rare Disease Treatment","summary":"Healx reported positive Phase 2 results for its rare disease treatment, marking a significant milestone in the development of the therapy.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOSl9DVC1pRkJMd1ZzUjA0bzlDOUVEaUxOZ0JFeUsyUmNXSmhneGZ0WjRKRGh2aUZlcHlPdEl0N2xTUjNZa1I5QkV0b2NnUmhuVDN5S2VnaE1ZT01MZUp4UGczeUtRME9VSVhBRjBLN0d2S1RQelA1MlJtOXR3cGpIeVBVRGlIanpZR1lCdU9KOTFoUGFi?oc=5","date":"2021-07-22","type":"pipeline","source":"Pharmaceutical Technology","summary":"Healx: AI-driven drug repurposing for rare disease - Pharmaceutical Technology","headline":"Healx: AI-driven drug repurposing for rare disease","sentiment":"neutral"}],"patents":[{"drugName":"Healx-101","drugSlug":"generic-name","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":5,"keyCompetitors":["Ionis Pharmaceuticals","Biogen","Pfizer"],"therapeuticFocus":["Rare Diseases","Neurological Disorders"],"financials":null,"yahoo":null}